Manu Chaudhary,
Anurag Payasi 
For correspondence:- Anurag Payasi Email: ccmb@venusremedies.com Tel:+911795302005
Received: 1 February 2013 Accepted: 3 February 2014 Published: 23 April 2014
Citation: Chaudhary M, Payasi A. Evaluation of Genotoxicity of CSE1034 by Ames and In vitro Chromosomal Aberration Tests. Trop J Pharm Res 2014; 13(4):527-532 doi: 10.4314/tjpr.v13i4.6
© 2014 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To evaluate the genotoxicity of CSE1034, a novel antibiotic adjuvant entity, using bacterial reverse mutation assay (Ames test) and in vitro chromosomal aberration test.
Methods: Reverse mutation test was carried out using four strains of Salmonella typhimurium (TA 98, TA100, TA1535 and TA1537) and one strain of E. coli [WP2 (uvrA)], while chromosomal aberration test was done with cultured Chinese hamster lung (CHL) cells. Reverse mutation test was carried out in a dose range of 0.0015 to 0.16 µg/plate in triplicate with and without S9 activation.
Results: No significant increases in the number of revertants were observed at the dose levels where antibacterial effects were not noted. CSE1034 caused no increase in the number of chromosomal aberrants at dose levels of 0.34, 0.69, 1.37, 2.75 and 5.50 mg/ml in the absence and presence of metabolic activation.
Conclusion: Based on the above observations, it can be concluded that CSE1034 has no mutagenic activity.
Archives
News Updates
Fulltext in PDF